Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
7.05 USD | -5.62% | -4.31% | -18.85% |
Jun. 05 | Morgan Stanley Adjusts COMPASS Pathways Price Target to $23 From $30, Maintains Overweight Rating | MT |
Jun. 04 | FDA panel to review psychedelic drug MDMA for first time | RE |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-18.85% | 511M | |
+57.44% | 59.34B | |
+43.17% | 40.24B | |
-4.87% | 39.88B | |
-5.56% | 28.55B | |
+15.07% | 27.26B | |
-21.04% | 19.23B | |
+32.60% | 12.61B | |
+2.59% | 12.49B | |
+25.92% | 12.28B |
- Stock Market
- Equities
- CMPS Stock
- News COMPASS Pathways plc
- Compass Pathways Insider Sold Shares Worth $597,964, According to a Recent SEC Filing